Cases & Deals

Share

Baxter Ventures invests in Zytoprotec

February 2013

Client(s) Baxter International Inc.

Jones Day advised Baxter Ventures in connection with its investment in Zytoprotec GmbH, an Austrian biotechnology company applying findings in the area of cytoprotection to develop new treatment options for major diseases.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.